Clinical-stage biopharmaceutical company, Abeona Therapeutics Inc., is at the forefront of developing gene and cell therapies to address life-threatening diseases. The company's flagship clinical program, EB-101, an autologous engineered cell therapy, is currently undergoing Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. In addition, the company's pipeline includes ABO-503 for X-linked retinoschisis treatment, ABO-504 for stargardt disease, and ABO-505 for autosomal dominant optic atrophy. Abeona is also committed to advancing AAV-based gene therapy through its AIM vector platform programs. In June 2015, the company changed its name from PlasmaTech Biopharmaceuticals, Inc. to Abeona Therapeutics Inc. and has its headquarters in New York City.
Abeona Therapeutics's ticker is ABEO
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at Abeona Therapeutics
It is abeonatherapeutics.com
Abeona Therapeutics is in the Healthcare sector
Abeona Therapeutics is in the Biotechnology industry
The following five companies are Abeona Therapeutics's industry peers: